Pyxis Oncology

Pyxis Oncology, Inc. engages in the development of antibody therapeutics. The company was founded by David Steinberg, Shaan Gandhi, and John Flavin on June 11, 2018 and is headquartered in Cambridge, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Boston, MA.

Pyxis Oncology completed an acquisition of Apexigen, adding to its pipeline and bringing in a drug called sotigalimab. Pyxis Oncology's pipeline includes PYX-106 and PYX-201, with preliminary data expected in late 2023 and early 2024, respectively. The company has a strong financial position with cash and investments of $144.1 million, enough to last into the first half of 2025.

Pyxis Oncology: Catalysts Ahead, Cash In Hand And An Acquisition Completed

BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced its participation in two upcoming investment conferences.

Pyxis Oncology to Participate in Two Upcoming Investment Conferences

Transaction adds a validated antibody-discovery platform, Phase 2 candidate and royalty stream Company positioned as a leader in next-generation, end-to-end Antibody-Drug Conjugate (“ADC”) creation with clinically and commercially validated platform capabilities Cash runway maintained into 1H 2025, enabling the Company to evaluate early signs of potential clinical activity for PYX-201 and PYX-106 Guidance on development strategy, timelines and milestones for the newly acquired Phase 2 sotigalimab CD40 agonist to be shared in 4Q23 BOSTON, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS) (“Pyxis Oncology” or the “Company”), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced the successful completion of its acquisition of Apexigen, Inc. (“Apexigen”), a clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody therapeutics for oncology, in an all-stock transaction valued at approximately $10.7 million. The combined company is positioned at the forefront of ADC innovation with a platform that now includes four key components: novel humanized antibody generation capabilities, an expanded library of linkers with improved stability, site specific conjugation chemistries, and optimized payloads.

Pyxis Oncology Successfully Completes Acquisition of Apexigen

Pyxis Oncology, Inc. (PYXS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -15.56% in 4 Weeks, Here's Why You Should You Buy the Dip in Pyxis Oncology, Inc. (PYXS)

Third dose cohort initiated in Phase 1 trial of PYX-201, Pyxis Oncology's first ADC product candidate Preliminary data from two Phase 1 trials on track for late 2023 to early 2024 Apexigen transaction anticipated to close later in August Strong balance sheet with $144 million in cash (including restricted cash) and short-term investments supports operations into 1H 2025 BOSTON, Aug. 11, 2023 (GLOBE NEWSWIRE) --  Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today reported financial results for the quarter ended June 30, 2023, and provided a corporate update. Pyxis Oncology ended the second quarter of 2023 with approximately $144.1 million in cash, cash equivalents, restricted cash and short-term investments, which is expected to provide a runway into the first half of 2025, enabling the Company to evaluate early signs of potential clinical activity for PYX-201 and PYX-106 and potentially allowing the Company to initiate tumor-specific expansion cohorts following dose selection.

Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update

Apexigen Inc

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Apexigen, Inc. (NasdaqCM: APGN) to Pyxis Oncology, Inc. (NasdaqGS: PYXS). Under the terms of the proposed transaction, shareholders of Apexigen will receive 0.1725 shares of Pyxis for each share of Apexigen that they own. KSF is seeking to determine whether this consideration and the process that led to it are.

APEXIGEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN

BOSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President and Chief Executive Officer, will present a company overview at the BTIG Virtual Biotechnology Conference on August 7, 2023 at 3:00 PM EST. The Pyxis Oncology management team will also host investor meetings that same day. To join the conference, email info@btig.com.

Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference

Pyxis Oncology, Inc. (PYXS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Pyxis Oncology, Inc. (PYXS) Upgraded to Strong Buy: What Does It Mean for the Stock?

The two industry leaders focus on navigating the biotech industry and immuno-oncology research The two industry leaders focus on navigating the biotech industry and immuno-oncology research

CancerVAX CEO Ryan Davies Discusses Biotech Entrepreneurship with Pyxis Oncology CEO Dr. Lara Sullivan

An anti-EDB ADC, known as PYX-201 is being explored in a phase 1 study treating patients with breast, head and neck, lung and thyroid cancer. An anti-Siglec-15 drug, known as PYX-106, is being advanced in a phase 1 study treating patients with Bladder, Cholangio-carcinoma, Colorectal, and Kidney Cancer. Results from the phase 1 studies using PYX-106 and PYX-201 are expected in late 2023 and early 2024 respectively.

Pyxis: Unique ADC Approach With A Catalyst In Late 2023

Pyxis Oncology is developing next-generation therapeutics, including antibody-drug conjugates and immuno-oncology programs, to target solid tumors resistant to current treatments. PYXS's lead product candidates, PYX-201 and PYX-106, are currently in Phase 1 clinical trials, with promising preclinical results and unique targeting mechanisms. Pyxis Oncology presents a 'Buy' opportunity for high-risk-tolerant investors, but investors should monitor the progress of ongoing Phase 1 trials and the competitive landscape.

Pyxis Oncology: A High-Stakes Gambit In The Battle Against Solid Tumors

Pyxis' (PYXS) shares rise as the company advances its phase I candidates, PYX-106 and PYX-201, for challenging cancer therapies.

Pyxis (PYXS) Up on Advancing Cancer Therapy Candidates

APEXIGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN

First subject dosed in Phase 1 trial of PYX-106, a fully human immunotherapy antibody candidate Second dose level initiated in Phase 1 trial of PYX-201, an antibody-drug conjugate (ADC) candidate Preliminary data from both trials on track for late-2023/early-2024 timeframe Company to present and host investor meetings at Jefferies Healthcare Conference in NYC on June 7, 2023 BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced dosing of the first subject in the Phase 1 trial of PYX-106. PYX-106 is a fully human immunotherapy antibody candidate that is designed to block the activity of Siglec-15, an immune suppressor expressed across a broad range of tumors.

Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs

Pyxis Oncology positioned at forefront of Antibody-Drug Conjugate (ADC) development Commercially and clinically validated APXiMAB platform for antibody generation complements FACT ADC toolkit of linkers, payloads and conjugation chemistries previously obtained from Pfizer Sotigalimab, a potential best-in-class Phase 2 CD40 agonist, has demonstrated rapid, deep and durable responses across difficult-to-treat tumor types All-stock deal allows Pyxis Oncology to maintain cash runway into 1H 2025; PYX-201 and PYX-106 remain on track Webcast to be held today, May 24, at 9:00 a.m. ET BOSTON and SAN CARLOS, Calif.

Pyxis Oncology to Acquire Apexigen

Getaround Inc

SoundHound AI Inc

Penny stocks to watch as sympathy momentum puts focus on stocks under $5 today. The post 3 Top Penny Stocks To Watch As GSIT, OMH Stock Explode appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Top Penny Stocks To Watch As GSIT, OMH Stock Explode

Orphan Drug Designation received for PYX-201 in pancreatic cancer Preliminary data from two Phase 1 trials anticipated late 2023 to early 2024 Strong balance sheet with $150.8 million in cash (including restricted cash) and short-term investments and no debt supports operations into 1H 2025 BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today reported financial results for the quarter ended March 31, 2023, and provided a corporate update. Pyxis Oncology ended the first quarter of 2023 with approximately $150.8 million in cash, cash equivalents, restricted cash and short-term investments, which is expected to provide a runway into the first half of 2025, enabling the Company to evaluate early signs of potential clinical activity for PYX-201 and PYX-106 and initiate tumor-specific expansion cohorts following dose selection.

Pyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update

Ambev

Bird Rides

Use these tips to avoid losing money with penny stocks The post Why Am I Losing Money With Penny Stocks? 3 Reasons  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Why Am I Losing Money With Penny Stocks? 3 Reasons

Imperial Petroleum

Summit Wireless Technologies Inc

Are you making these penny stocks trading mistakes? The post Beginner Penny Stocks Trading Mistakes: 3 to Avoid  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Beginner Penny Stocks Trading Mistakes: 3 to Avoid

PYXS has initiated dosing with PYX-201 in a phase 1 study, with preliminary results due in early 2024. PYXS expects to initiate dosing in a phase 1 study of PYX-106 in Q2'23, which could add additional readouts to the 2024 calendar.

Pyxis Oncology: Cashed Up And Entering The Clinic

Preliminary data from two Phase 1 trials anticipated late 2023 to early 2024

Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update

Milestone marks transition of Pyxis Oncology to a clinical-stage company

Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors

CAMBRIDGE, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced that Lara Sullivan, M.D., President and Chief Executive Officer, Pamela Connealy, Chief Financial Officer, Jay Feingold, M.D., Ph.D., Chief Medical Officer, and Jan Pinkas, Ph.D., Chief Scientific Officer, will host investor meetings on February 15, 2023 as part of the SVB Securities Global Biopharma Conference, taking place virtually.

Pyxis Oncology to Participate in the Virtual 2023 SVB Securities Global Biopharma Conference

FDA grants IND clearances of PYX-201, a novel antibody-drug conjugate (ADC) product candidate, and PYX-106, an immunotherapy product candidate

Pyxis Oncology Announces FDA Clearance of Two IND Applications

Expands worldwide licensing agreement with Pfizer to obtain additional antibody-drug conjugate (ADC) platform components

News for Pyxis Oncology Stock (PYXS)